Which statement best describes the effect of dexmedetomidine on cerebral blood flow and cerebral metabolic rate for oxygen and intracranial pressure (ICP)?

Which statement best describes the effect of dexmedetomidine on cerebral blood flow and cerebral metabolic rate for oxygen and intracranial pressure (ICP)?

• A. Increases CBF with increased CMRO2
• B. No change in CBF, CMRO2, or ICP
• C. Decreased CBF with no change in CMRO2 and ICP
• D. Decreased CMRO2 with decreased ICP

Answer: (C)

Dexmedetomidine lowers cerebral blood flow primarily through cerebral vasoconstriction mediated by alpha-2 adrenergic receptors. At the same time, it dampens neuronal activity and lowers metabolic demand, so the brain’s requirement for oxygen doesn’t rise; in many clinical discussions this balance is described as not changing the metabolic rate for oxygen by a meaningful amount. Because the reduction in blood flow is matched by the relatively stable or only minimally changed metabolic demand, intracranial pressure tends not to rise and often stays the same. So the statement that best fits this pattern is the one describing a decrease in cerebral blood flow with no significant change in metabolic rate for oxygen and no change in intracranial pressure. This reflects the drug’s tendency to reduce flow without driving ICP up, while the metabolic demand remains essentially unchanged from baseline in a way that doesn’t provoke pressure changes.

Dexmedetomidine lowers cerebral blood flow primarily through cerebral vasoconstriction mediated by alpha-2 adrenergic receptors. At the same time, it dampens neuronal activity and lowers metabolic demand, so the brain’s requirement for oxygen doesn’t rise; in many clinical discussions this balance is described as not changing the metabolic rate for oxygen by a meaningful amount. Because the reduction in blood flow is matched by the relatively stable or only minimally changed metabolic demand, intracranial pressure tends not to rise and often stays the same.

So the statement that best fits this pattern is the one describing a decrease in cerebral blood flow with no significant change in metabolic rate for oxygen and no change in intracranial pressure. This reflects the drug’s tendency to reduce flow without driving ICP up, while the metabolic demand remains essentially unchanged from baseline in a way that doesn’t provoke pressure changes.